Featured Research

from universities, journals, and other organizations

New test for patients with sore throats cuts antibiotic use by nearly a third

Date:
November 8, 2013
Source:
University of Southampton
Summary:
A new 'clinical score' test for patients with sore throats could reduce the amount of antibiotics prescribed and result in patients feeling better more quickly, research shows.

A new 'clinical score' test for patients with sore throats could reduce the amount of antibiotics prescribed and result in patients feeling better more quickly, research in the British Medical Journal shows.

Researchers at the University of Southampton, funded by the National Institute for Health Research (NIHR) Heath Technology Assessment (HTA) Programme, used the five-item FeverPAIN score to decide whether to prescribe patients with an antibiotic immediately or to give them a delayed prescription and compared it with simply offering a delayed prescription.

The FeverPAIN score includes; fever in the past 24 hours, a pus infection, rapid attendance (within three days), inflamed tonsils and no cough or cold symptoms.

Results showed that using the test reduced antibiotic use by almost 30 per cent and despite using fewer antibiotics, patients in the FeverPAIN score group experienced a greater improvement in symptoms.

But the use of an in-practice rapid antigen test (a test which detects the bacteria, Lancefield Group A Streptococcus, which is the most common bacterium to cause sore throats) in conjunction with the FeverPAIN score did not result in any further reductions in antibiotic use or improvements in symptoms.

Paul Little, Professor of Primary Care Research who led the research, comments: "Our findings show that using this clinical score test can target antibiotics more effectively and help persuade patients antibiotics are not needed.

"Additionally the FeverPAIN score should enable better targeting of antibiotics than the current scoring system to identify the likelihood of a bacterial infection in patients complaining of a sore throat, as it allows GPs to rule out likely streptococcal infection in more patients."

The study recruited 631 patients with an acute sore throat and compared use of the FeverPAIN clinical score, with or without rapid antigen testing, with a delayed prescription, in which patients were told to pick up a prescription three to five days later if their symptoms did not settle or got worse.

Patients who had four or five of the clinical features of the FeverPAIN test were prescribed antibiotics immediately; a delayed antibiotic prescription was offered to patients with two or three features and no antibiotics to those with only one or no features.

The test led to a 29 per cent reduction in antibiotic use compared with the delayed prescription approach. One in three patients in the FeverPAIN score group said their sore throat had improved rapidly from a moderately bad problem to a slight problem within two to four days. Moderately bad or worse symptoms also got better faster in the clinical score group.

However, the use of a rapid antigen test as well as the FeverPAIN test for patients who displayed streptococci symptoms did not offer any further improvements, with a 27 per cent reduction in antibiotic use as well as similar improvements in patients' symptoms.

Study co-author Dr Michael Moore, a GP and a reader in primary care research at the University of Southampton, adds: "Clinicians can consider using a clinical score to target antibiotic use for acute sore throat, which is likely to reduce antibiotic use and improve symptom control. There is no clear advantage in the additional use of a rapid antigen test.

"We found that the FeverPAIN score picks up bacterial throat infections more accurately than the current scoring system and importantly picks up larger numbers of patients who are at low risk of streptococcal infection giving the patient and the doctor the confidence not to use antibiotics. If you select those at the highest risk of streptococcal infection then antibiotics can be more targeted at the people who are most likely to get symptom benefit."


Story Source:

The above story is based on materials provided by University of Southampton. Note: Materials may be edited for content and length.


Journal Reference:

  1. P. Little, F. D. R. Hobbs, M. Moore, D. Mant, I. Williamson, C. McNulty, Y. E. Cheng, G. Leydon, R. McManus, J. Kelly, J. Barnett, P. Glasziou, M. Mullee. Clinical score and rapid antigen detection test to guide antibiotic use for sore throats: randomised controlled trial of PRISM (primary care streptococcal management). BMJ, 2013; 347 (oct10 3): f5806 DOI: 10.1136/bmj.f5806

Cite This Page:

University of Southampton. "New test for patients with sore throats cuts antibiotic use by nearly a third." ScienceDaily. ScienceDaily, 8 November 2013. <www.sciencedaily.com/releases/2013/11/131108102333.htm>.
University of Southampton. (2013, November 8). New test for patients with sore throats cuts antibiotic use by nearly a third. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/11/131108102333.htm
University of Southampton. "New test for patients with sore throats cuts antibiotic use by nearly a third." ScienceDaily. www.sciencedaily.com/releases/2013/11/131108102333.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins